Xeris Biopharma Holdings, Inc.
Price Action
Technical Summary
WEAKENINGXeris Biopharma Holdings, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 29), showing significant lag compared to the market leaders. Earnings growth of 117% provides fundamental context to the price action. Investors should exercise caution due to high volatility (59% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.15 | +7.84% | ABOVE |
| 50 SMA | $5.92 | +12.06% | ABOVE |
| 100 SMA | $6.58 | +0.81% | ABOVE |
| 150 SMA | $7.06 | -6.09% | BELOW |
| 200 SMA | $7.08 | -6.37% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is XERS in an uptrend right now?
XERS has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is XERS overbought or oversold?
XERS's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.
Is XERS outperforming the market?
XERS has a Relative Strength (RS) Rating of 29 out of 99. XERS is currently lagging the broader market.
Where is XERS in its 52-week range?
XERS is trading at $6.63, which is 66% of its 52-week high ($10.08) and 40% above its 52-week low ($4.30).
How volatile is XERS?
XERS has a Beta of 1.04 and 52-week volatility of 59%. It's more volatile than the S&P 500 - expect bigger swings.